Bortezomib
Product Images NDC 50742-484

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 50742-484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bortezomib 01)

Chemical structure of bortezomib, illustrating its molecular composition including boronic acid groups, amide bonds, and aromatic rings characteristic of the active ingredient.*

FDA Label Image

Figure 1 (Bortezomib 02)

A line graph showing patient survival over time (months) comparing two treatment groups labeled Vc-MP (red line) and MP (blue line). The y-axis represents percentage of patients, and the x-axis represents time in months up to 24. Supporting text details the number of patients at risk over time and a p-value from a log-rank test indicating statistical analysis.*

FDA Label Image

Figure 2 (Bortezomib 03)

A Kaplan-Meier survival curve chart depicting the percentage of patients over time (months) comparing two treatment groups: Vc-MP (red dashed line) and MP (blue solid line). The x-axis represents time in months up to around 78 months, and the y-axis shows the percentage of patients from 0 to 100%. The chart includes a table with the number of patients at risk at different time points for both groups and a note indicating a p-value from a log-rank test (p < 0.05).*

FDA Label Image

Figure 3 (Bortezomib 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time in days between Bortezomib and Dexamethasone treatments. The y-axis represents the proportion of patients, while the x-axis shows time in days. Bortezomib's data is plotted with a blue solid line with circles, and Dexamethasone's data is plotted with a red dashed line with triangles. The graph indicates patient numbers at various timepoints and includes a p-value from a log-rank test.*

FDA Label Image

Figure 4 (Bortezomib 05)

This Kaplan-Meier survival curve compares the proportion of patients over time (days) receiving Bortezomib versus Dexamethasone. The plot shows patient survival probability on the vertical axis and time in days on the horizontal axis, with data points and the number of patients remaining at various timepoints indicated below. The graph includes a p-value from a log-rank test, highlighting statistical comparison between the two treatments.*

FDA Label Image

Figure 5 (Bortezomib 06)

A survival curve chart comparing the percentage of patients over time (months) for two treatment groups, VcR-CAP and R-CHOP. The y-axis shows percentage of patients, and the x-axis shows time in months up to 66. The chart includes subject counts at risk for both groups at various time points and a log rank test p-value less than 0.001.*

FDA Label Image

Figure 6 (Bortezomib 07)

A survival curve chart depicting the percentage of subjects alive over months from randomization for two treatments, VcR-CAP and R-CHOP. The solid line represents VcR-CAP and the dashed line represents R-CHOP. The chart includes a table of subjects at risk over time and a hazard ratio with 95% confidence interval.*

FDA Label Image

Principal Display Panel (3.5 mg Vial Label)

Label for Bortezomib for Injection, 3.5 mg per vial, a single-dose vial containing lyophilized bortezomib and mannitol. The label indicates use for intravenous or subcutaneous injection, warns of cytotoxicity, and includes storage instructions. Manufactured by Ingenus Pharmaceuticals, LLC.*

FDA Label Image

Principal Display Panel (3.5 mg Vial Carton)

Packaging label for Bortezomib for Injection 3.5 mg/Vial by Ingenus Pharmaceuticals, LLC. The label specifies it as a single-dose vial intended for intravenous or subcutaneous use, with a caution that it is a cytotoxic agent. The label includes reconstitution instructions, storage conditions, and dosage information references. It features the NDC number 50742-484-01 and barcode.*

FDA Label Image

Principal Display Panel Inside Flap (all Cartons) (Bortezomib 10)

Unfolded carton for Bortezomib by Ingenus Pharmaceuticals, LLC, showing reconstitution information. The label details volumes of 0.9% Sodium Chloride to add for subcutaneous (1.4 mL for 2.5 mg/mL concentration) and intravenous (3.5 mL for 1 mg/mL concentration) injection forms. The design includes fold and cut lines.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.